Epstein–Barr Virus: Biology and Early Infection
Epstein–Barr virus (EBV), also known as human herpesvirus 4 (HHV-4), is a member of the Herpesviridae family, subfamily Gammaherpesvirinae, genus Lymphocryptovirus. EBV was first identified in 1964 in Burkitt’s lymphoma, marking the first clear link between an infectious agent and human cancer. Since then, EBV has become a paradigm for virus–host interaction, viral latency, and virus-driven oncogenesis.
A defining feature of EBV—shared with all herpesviruses—is its ability to establish lifelong persistence. EBV tightly controls host cell metabolism and alternates between two phases of its life cycle: a lytic phase, characterized by productive viral replication, and a latent phase, in which the viral genome persists as an episome in long-lived memory B cells with highly restricted gene expression.
Today, EBV is associated with a broad spectrum of diseases, including:
- Hodgkin lymphoma
- post-transplant lymphoproliferative disorders (PTLD)
- non-Hodgkin lymphomas in HIV-positive individuals
- T-cell and NK/T-cell lymphomas
- nasopharyngeal carcinoma
- certain forms of gastric cancer
Beyond malignancies, EBV causes
- infectious mononucleosis and
- oral hairy leukoplakia
in immunocompromised patients and has been implicated in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.
Virion Architecture and Genome Organization
Structurally, EBV closely resembles other herpesviruses. The virion has a diameter of approximately 125 nm and consists of three layers:
- A lipid envelope derived from host membranes, studded with host cell surface proteins and viral glycoproteins that determine cell tropism and mediate membrane fusion.
- A pseudo-icosahedral nucleocapsid, composed of major and minor capsid proteins assembled into 150 hexamers and 11 pentamers, together with a unique portal protein.
- A pleomorphic tegument, consisting of 20–40 viral proteins, positioned between envelope and capsid. Embedded within this layer is the capsid-associated tegument complex (CATC).
The EBV genome within the nucleocapsid is a linear double-stranded DNA molecule of approximately 170–180 kb, encoding 85–100 viral proteins and 44 viral microRNAs. At both termini, the genome contains two complementary regions at the ends of 538 bp terminal repeats (TRs), which anneal and ligate after infection, allowing circularization of the genome into an episome. In addition, four internal repeat regions (IR1–IR4) divide the genome into five unique regions (U1–U5) and are closely linked to EBV’s transforming ability.
Cell Tropism and Entry Pathways
EBV exhibits a pronounced tropism for pharyngeal epithelial cells and B lymphocytes, using distinct but related entry mechanisms in each cell type—an important consideration for peptide-based studies of viral entry and antigen presentation.
Entry into Epithelial Cells
In epithelial cells, EBV attachment is initiated by the interaction of the viral glycoprotein BMRF2 with cellular integrins via a conserved RGD (arginine–glycine–aspartate) motif.
A similar integrin-binding motif in gH, as part of the gH/gL complex, further stabilizes virus–cell contact.
Ultimately, gB is recruited and membrane fusion is executed by the conserved herpesviral fusion machinery formed by gH/gL and gB, allowing delivery of the nucleocapsid into the cytoplasm.
Entry into B Lymphocytes
*gp350/220 are two isoforms of 350 kDa and 220 kDa with identical function. The shorter splice variant gp220 is also named gp340 reflecting historical conventions, assay-dependent detection, and differences in glycosylation.
Explore peptides&elephants' 👉 EBV (GP350/GP340) Peptide Pool and the epitope 👉EBV BALF-4 276–284 (HLA-A*02:01) derived from envelope glycoprotein B, encoded by the BALF4 open reading frame.
Earliest Cytoplasmic and Nuclear Events (Pre-Latent Phase)
Following membrane fusion, the uncoated EBV is released into the cytosol, marking the beginning of the pre-latent phase. At this stage, the outer tegument proteins rapidly dissociate. These proteins are primary effectors: they restrict host protein synthesis, counteract apoptosis, and remodel cellular metabolism to favor viral persistence. Many of them are constitutively produced during the lytic stage, implicating an importance for viral replication.
In contrast, inner tegument proteins, most notably BPLF1, remain in part capsid-associated and interact with the cellular cytoskeleton. Through interactions with dyneins and microtubule plus-end associated proteins (+TIPs), the nucleocapsid is actively transported toward the centrosome near the nucleus. Subsequent trafficking to the nuclear membrane is thought to resemble the mechanism described for herpes simplex virus type 1 (HSV-1), involving nuclear localization signals and interactions with the nuclear pore complex (NPC) – probably mediated by BPLF1.
The delivery of the viral DNA into the nucleus occurs through the nuclear pore and is driven by intracapsid pressure, analogous to genome release in bacteriophages. Once inside the nucleus, the linear EBV genome circularizes via its terminal repeats, forming a stable episome—the molecular foundation for EBV latency and long-term persistence.
Explore peptides&elephants' epitope 👉EBV BPLF1 1395–1407 — a valuable tool for studying EBV-specific CD4⁺ T cell responses, antigen presentation via HLA-DR molecules, and immune recognition of tegument-associated viral proteins.
From Structural Entry to Transcriptional Control
With the viral genome successfully circularized and established as a nuclear episome, EBV transitions from structural entry events to transcriptional control.
What follows is a highly dynamic early phase in which viral gene expression, host cell survival, and immune evasion become tightly interconnected.
Now residing in the nucleus, EBV initiates a carefully orchestrated transcriptional program that drives proliferation while simultaneously preventing apoptosis. This early reprogramming determines whether the infected B cell will undergo transformation, immune elimination, or stable latency.
Peptide-based tools provide powerful means to dissect these regulatory mechanisms at the molecular level.
The Pre-Latent Phase: Survival First
Although the viral genome is now maintained as an episome, transcription does not immediately follow a strictly ordered latency program. Most EBV-infected cells remain in the G0 phase of the cell cycle. During the first 1–2 weeks after infection, the viral genome is largely unmethylated, and lytic and latent genes are expressed in a partially disordered pattern. This stage is commonly referred to as the pre-latent abortive lytic phase.
While not leading to full viral replication, this phase is functionally crucial. Transient expression of lytic components—including BCL-2-like anti-apoptotic proteins and inhibitors of HLA expression—creates a protected intracellular environment. Apoptosis is suppressed, antigen presentation is reduced, and the infected cell is stabilized long enough for a structured latency program to emerge.
Establishment of Infection via Defined Promoter Usage
As transcriptional control becomes more organized, EBV gene expression shifts toward defined promoter usage. Transcription initiates at the Wp promoter cluster within the internal repeat region IR1 of the episomal genome. Wp controls expression of EBNA2 and EBNA-LP, two key transcriptional coactivators.
EBNA2 can interact with thousands of sites across the host genome. In cooperation with EBNA-LP, it:
- Suppresses transcriptional repressors
- Enhances transcriptional activators
- Reprograms both viral and cellular gene expression
A central outcome of this reprogramming is activation of the cellular proto-oncogene MYC: EBNA2, together with EBNA-LP, probably activates an enhancer upstream of the host’s MYC gene. Through interactions with other cellular factors, this enhancer is brought into proximity with the MYC promoter.
MYC is a master regulator that stimulates transcription of thousands of genes, many of which promote cell cycle progression. Temporary MYC accumulation during early infection:
- drives rapid B-cell proliferation
- promotes survival before viral latency proteins are fully established
- enables escape from apoptosis during early infection
However, sustained MYC overexpression is inherently pro-apoptotic and oncogenic. Therefore, its activity must be tightly controlled.
Switching from Wp to Cp: Transition to Organized Latency
Within 1–3 days after infection, EBNA2 strongly activates the Cp promoter, located upstream of Wp on the EBV episome. During this period, lytic anti-apoptotic proteins such as BHRF1 and BALF1 are abundant and cell proliferation is extremely rapid (mitosis ~every 8 hours).
Cp drives expression of all EBNA proteins from a single polycistronic transcript, which is processed by alternative splicing. This transcriptional configuration—producing EBNA1, EBNA2, EBNA-LP, and the EBNA3 family—is referred to as latency program IIb.
As a result, viral transcription gradually transitions from strong proliferative drive to regulated persistence. The shift from Wp to Cp likely enables this controlled transition.
For EBV research and the analysis of EBNA2-specific immune responses, peptides&elephants offers both the defined epitope peptide 👉 EBV EBNA2 280–290 (DRB1*01:01) and a comprehensive 👉 EBV EBNA-2 Peptide Pool covering the full antigen sequence—ideal tools for T-cell assays, epitope mapping, and immune monitoring studies.
The EBNA3 Family: Balancing Proliferation and Survival
The EBNA3 family (EBNA3A, EBNA3B, EBNA3C) functions as transcription factors and plays a central regulatory role during latency IIb. These proteins counterbalance EBNA2-driven MYC activation and prevent apoptosis.
Literature
Zaremba, Andrii et al. “A thorough insight into the life cycle of the Epstein-Barr virus. From the molecular to the organismal level.” Current research in microbial sciences vol. 9 100505. 3 Nov. 2025, doi:10.1016/j.crmicr.2025.100505